Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ONO-5788 in Healthy Volunteers
NCT03571594Phase 1Terminated
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ONO-5788 in acromegaly (11 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Number of participants with treatment emergent adverse events by severity at Day 28, Number of participants with serious adverse events (SAEs) at Day 28 and 4 more. Started Jun 2018; status: terminated.
02
Drugs
ONO-5788
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT03571594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571594.